RESUMO
Módolo NSP, Azevedo VLF, Santos PSS, Rosa ML, Corvino DR, Alves LJSC -Estratégia Anestesiológica para Cesariana em Paciente Portadora de Deficiência de Fator XI. Relato de Caso. 
JUSTIFICATIVA E OBJETIVOS: A deficiência do fator XI é uma doença hematológica rara na população. A hemofilia C (deficiência do
fator
INTRODUCTION
the following is a list of coagulation factors in the plasma: Ifibrinogen; II -prothrombin; III -thromboplastin; IC -calcium; v -labile factor; vI -prothrombinase; vII -stable factor; vIII -antihemophilic globulin; IX -Christmas factor PtC; X -Stuart-Power factor; XI -PtA; XII -Hageman factor; XIII -fibrin stabilizing factor 1 . According to the International Commission on nomenclature of the World Health organization (WHo), the classification of bleeding disorders is based on the deficient factor: 1) Fibrinogen I deficiency: afibrinogenemia, hypofibrinogenemia. 2) deficiency of fibrin stabilizing factor XIII. 3) Prothrombin deficiency. 4) deficiency of prothrombin activating factors: a) extrinsic pathways: factor v deficiency or parahemophilia; factor vII deficiency; factor X deficiency. b) Intrinsic pathway: factor vIII deficiency (hemophilia A); factor IX deficiency (hemophilia B); factor XI deficiency (hemophilia C); factor XII deficiency (Hageman disease). 5) deficiency associated with vascular and plasmatic factor (von Willebrand disease).
Factor XI deficiency or hemophilia C is a rare hematologic disease. Unlike hemophilia A (factor vIII deficiency), hemophilia C affects both genders and it is usually asymptomatic, manifesting only as postoperative bleeding 2 . It is an autosomal recessive disorder 3,4 , homozygous or heterozygous, and the severity depends on the levels of factor XI, being classified as severe with levels of 4% to 20%, and moderate to mild between 20% and 65% 5 . Activation of factor X is necessary for the conversion of prothrombin in thrombin and for the action of this compound on fibrinogen, transforming it in fibrin, followed by factor XIII, which stabilizes the fibrin clot. Factor vIII deficiency (hemophilia A), factor IX deficiency (hemophilia B), factor XI deficiency (hemophilia C), besides factor vII deficiency and the acquired deficiency of the inhibitors of those factors, are the most common hereditary disorders that compromise the activation of factor X. those deficiencies are translated in prolongation in activated partial thromboplastin time (aPtt), which, when present, should lead to the investigation of those factors or their inhibitors 6 . Factor XI has an important role in reducing fi-brinolysis, and patients with deficiency of this factor are prone to hemorrhagic episodes in tissues with increased fibrinolytic activity, such as tonsils, prostate, uterus, and oral cavity 5, 7 . Factor XI has a half-life of 40 to 80 hours 5 . A clear consensus on which level of factor XI is necessary for hemostasis during surgery does not exist, but the limit of 45 IU.dL -1 and 30 IU.dL -1 should be the goal for large and small surgeries, respectively 5 . Maintaining the levels of factor XI at approximately 30% is usually enough; however, some patients might need higher levels. The diagnosis of factor XI deficiency is confirmed by measuring its levels 7 . Patients with factor XI deficiency usually have prolonged aPTT and normal PT, although aPTT might be normal in heterozygous patients with mild deficiency. The levels of factors VIII and von Willebrand, as well as bleeding time and platelet function tests should also be investigated 5,7 , since it can be associated with platelet dysfunction. Prothrombin and thrombin time are normal in factor XI deficiency 7 .
Situations and suggestions for the management of patients with hemophilia C:
Preoperative: Fresh frozen plasma (FFP) (15-20 mL.kg -1 ) 3-9 , followed by postoperative maintenance with daily transfusion of FFP (5 mL.kg -1 ) 9 during one week, can be enough to prevent hemorrhagic complications after elective abdominal surgery in patients with severe factor XI deficiency 5 . Vaginal delivery: FFP or factor XI concentrate during and/or after vaginal delivery is not mandatory in women with severe factor XI deficiency, and they can be restricted to patients with severe hemorrhage 3 . Cesarean section: It seems that the same strategy (of the vaginal delivery) can be used 3 . It is possible that the tendency for bleeding complication after vaginal delivery or cesarean section is decreased due to the pregnancy-induced hypercoagulable state associated with high levels of fibrinogen and factors V, VII, VIII, IX, and XI 3 . Epidural block: It is not recommended, being contraindicated in patients with severe factor XI deficiency, except if prophylactic treatment with FFP or factor XI concentrate is administered 3 . Subarachnoid block: Safer than epidural block in patients with coagulopathies 1 . Patients who develop inhibitors: During surgery, they can be treated with recombinant factor VIIa 1 . Factor XI concentrate: This treatment is used in severe factor XI deficiency. The dose of 30 U.kg -1 is recommended 2-9 . Antifibrinolytic drugs used: Tranexamic acid, desmopressin, and fibrin glue 2 .
CASE REPORT
This 32 years old female, primigravida, on the 38 th week of pregnancy, was seen at the clinic for pre-anesthetic evaluation for cesarean section. The patient had factor XI deficiency followed-up by a hematologist. She had a history of myomectomy five years ago, during which she had severe postoperative bleeding; she was investigated at that time, receiving the diagnosis of factor XI deficiency. She had a history of several transfusions of FFP, and, on some occasions, she developed transfusional reactions. She stated she always had metrorrhagia which was explained as a consequence of uterine myomas. Physical exam did not show any abnormalities, and preoperative laboratorial exams showed: hemoglobin 11 g.dL -1 ; hematocrit, 34%; aPTT, 40 seconds; coagulation time, 8 minutes; bleeding time, 1 minute and 30 seconds; PT, normal; and INR, 1.0. According to the recommendations of the hematologist, on the day of the cesarean section the patient received oral promethazine (25 mg.kg -1 ), and intravenous hydrocortisone (500 mg.kg -1 ) and 700 mL of plasma (10 mL.kg -1 ). Repeated aPTT = 34.4 seconds. Two hours later, monitoring with cardioscope, pulse oximeter, non-invasive blood pressure, and urine output was instituted. A 27 x 3.5 Whitacre needle was used for the subarachnoid block, and 12.5 mg of 0.5% hyperbaric bupivacaine and 50 µg of morphine were administered. During the surgery, the patient received 2000 ml of Ringer's lactate. Dexamethasone (10 mg.kg -1 ) and ondansetron (4 mg.kg -1 ) were administered for prevention of nausea and vomiting, and cefazolin (2 mg.kg -1 ) was administered as antibiotic prophylaxis. Intercurrences were not observed during the anesthetic-surgical procedure and postoperative period; but on the 3 rd postoperative day, FFP (10 mL.kg -1 ) was administered for prophylaxis of late postoperative bleeding.
DISCUSSION
Factor XI deficiency, or hemophilia C, was described by Rosenthal et al. in 1953 -1 . It has an incomplete autosomal recessive inheritance. Hemophilia C has a frequency of 1/1,000,000 in the general population, but it is higher in Ashkenazi Jews, with an estimated gene frequency between 5% and 11%, and more than 0.3% are homozygous 2,5-9 . Deficiency results from three types of mutation: 1) changes in DNA segmentation, 2) interrupted DNA reading (stop codon), producing a non-functional molecule, and 3) amino acid substitution and molecular dysfunction 6 . Types II and III affect the ethnic group mentioned earlier 7 . It has few hemorrhagic manifestations, such as gingival bleeding, epistaxis, menorrhagia, and hematuria. However, significant bleeding can be seen after traumas or invasive procedures. Factor XI deficiency interferes with the coagulation cascade because it is one of the factors of the intrinsic pathway for factor X activation. Fresh frozen plasma (initial dose 15 ml.kg -1 , followed by 3 to 6 ml.kg -1 for 12 to 24 hours), or factor XI concentrate can be used in the treatment or prevention; the use of FEIBA (anti-inhibitor coagulant complex) is recommended 8 . In the case presented here, although the patient had a confirmed diagnosis of hemophilia C, since the levels of factor XI were unknown, preoperative preparation was necessary. The objective of this report was to present the anesthetic protocol for patients with hemophilia C, and to alert for the need to investigate cases with a prior history of postoperative bleeding; coagulation studies should be done before any invasive procedure and, if aPTT is prolonged, investigation of factor XI deficiency is mandatory. 
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